Abbvie Inc.

Abbvie Deutschland Gmbh and Co Kg

Novartis Ag

Abbott Gmbh & Co Kg

Abbott Laboratories Corporation

Abbvie Bahamas Limited

Abbvie Ireland Unlimited Company

Ulrich Westedt

Harald Hach

Yi Gao

Ute Lander

Martin Knobloch

Norbert Steiger

Terrence B Mazer

Gunther Berndl

Bernd Liepold

Thomas Kessler

Jörg Breitenbach

Jörg Rosenberg

Joerg Breitenbach

Normanella Dewille

Ping Tong

Nancy E Sever

Jianwei Wu

Mirko Pauli

Peter Hölig

Adivaraha Jayasankar

Rudolf Schroeder

Bryan K Erickson

Joerg Ogorka

Nicoletta Loggia

Colleen Garrett

Simon Kullmann

Gerd Woehrle

Ralf Altenburger

Marius Naris

Jörg Ogorka

Constanze Obermiller

Tanja Heitermann

Youngsuk Heo

Renato Koenig

Katrin Schneider

Michael Simon

Madlen Thiel

Juergen Weis

Brent D Sinclair

Benedikt Steitz

Dietrich Granzow

Tina Jung

Thomas Mueller

Samuel Kyeremateng

Katharina Asmus

Regina Reul

Donghua Zhu

Michael Siimon

Gary Katz

Douglas Wearly

Eik-Lang Lau

Peter Holig

Justin Lafountaine

The present invention features solid pharmaceutical compositions comprising Compound 1 and Compound 2. In one embodiment, the solid pharmaceutical composition includes (1) a first layer which comprises 100 mg Compound 1, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion; and (2) a second layer which comprises 40 mg Compound 2, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion.

Solid pharmaceutical compositions for treating HCV

A formulation comprising a melt-processed solid dispersion product comprising an active agent, a pharmaceutically acceptable thermoplastic polymer of N-vinyl lactams, and a pharmaceutically acceptable polyvinyl alcohol-polyalkylene glycol graft copolymer. A method for producing said formulation.

Solid retard formulations based on solid dispersions

The invention provides a dosage form, comprising a melt-processed mixture of (a) a pharmaceutically effective amount of imatinib or a salt thereof, (b) at least one polymeric binder, and (c) at least one pharmaceutically acceptable non-ionic surfactant. The invention provides imatinib dosage forms with high drug loading which can be prepared in a simple and efficient manner, imatinib dosage forms from which the active principle is released in an essentially pH-independent fashion, and extended release imatinib dosage forms.

Melt-processed imatinib dosage form

The present invention features solid compositions comprising Compound I, Ior I, or a pharmaceutically acceptable salt thereof, in an amorphous form. In one embodiment, Compound I, Ior I, or a pharmaceutically acceptable salt thereof, is formulated in an amorphous solid dispersion which comprises a pharmaceutically acceptable hydrophilic polymer and preferably a pharmaceutically acceptable surfactant.

Solid compositions

A description is given of a process for the preparation of a pharmaceutical composition of a macrolide antibiotic in essentially noncrystalline form, in which the macrolide antibiotic, a water-swellable polymer and a proton donor are blended in an extruder in the presence of water and forced through a die, the ratio by weight of the sum of macrolide antibiotic, water-swellable polymer and proton donor to water being at least 1:1. The macrolide antibiotic is preferably clarithromycin and the water-swellable polymer is preferably chosen from crosslinked polyvinylpyrrolidone, crosslinked sodium carboxymethylcellulose and crosslinked polyacrylic acid.

Preparation of compositions with essentially noncrystalline embedded macrolide antibiotics

Growing community of inventors

Schriesheim, Germany

Ulrich Westedt